Online inquiry

IVTScrip™ mRNA-Anti-PCSK9, AMG 145(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ2430MR)

This product GTTS-WQ2430MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets PCSK9 gene. The antibody can be applied in Type 2 diabetes (T2 DM) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_174936.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 255738
UniProt ID Q8NBP7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PCSK9, AMG 145(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ2430MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10477MR IVTScrip™ mRNA-Anti-CGRP, LY-2951742(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA LY-2951742
GTTS-WQ13018MR IVTScrip™ mRNA-Anti-CSF3R, PEG-G-CSF(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA PEG-G-CSF
GTTS-WQ11203MR IVTScrip™ mRNA-Anti-TNFRSF18, MEDI-1873(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MEDI-1873
GTTS-WQ12652MR IVTScrip™ mRNA-Anti-RSPO3, OMP-131R10(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA OMP-131R10
GTTS-WQ8017MR IVTScrip™ mRNA-Anti-CD52, GZ-402668(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA GZ-402668
GTTS-WQ1215MR IVTScrip™ mRNA-Anti-TPBG, ABR-217620(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ABR-217620
GTTS-WQ1672MR IVTScrip™ mRNA-Anti-IL1B, ACZ885(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ACZ885
GTTS-WQ12176MR IVTScrip™ mRNA-Anti-MSLN, MORAb-009(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MORAb-009
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW